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INTRODUCTION
The fast development from the laboratory to clinical appli­
cation of the haematopoietic growth factors (HGFs) is a rare 
event. The HGFs represenfa group of cytokines with well- 
defined effects on the haematopoietic system. They enable 
clinicians to modulate physiological and pathological proces­
ses and thus manage previously unresolved therapeutic pro­
blems. These advances were made possible by the progress of 
recombinant DNA technology.
Until now* three factors have been registered for clinical 
application: the myeloid growth factors G-CSF and granu­
locyte/macrophage colony stimulating factor (GM-CSF) and 
erythropoietin (EPO)> the main regulator of erythroid 
growth. Thrombopoietin (or megakaryocyte growth and 
differentiation factor) has been cloned recently and early 
clinical trials have already been launched. Only limited data 
are available regarding the combination of HGFs with one 
another or with earlier acting factors like stem cell factors 
(SCFs) that are able to prime haematopoietic progenitor 
cells for response to later acting factors like EPO. The 
recently cloned growth factor FLT 3 ligand stimulates the 
growth of primitive haematopoietic progenitor cells through 
synergistic interactions with multiple other cytokines.
Myeloid growth factors shorten significantly the duration 
of neutropenia following chemotherapy  ^ while the nadir 
usually remains unaffected [132]. It is also well known 
that prophylactic use of HGFs after myelosuppressive 
chemotherapy leads to a reduction in the incidence of 
febrile episodes3 the use of antibiotics and the number 
of days of hospitalisation for fever and/or infection [2- 4]. 
EPO exerts its maximal activity at the level of the more 
differentiated erythroid precursor cells. It is registered in 
most European countries for the treatment of renal anaemia. 
In more recent years3 it has also been convincingly demon­
strated that the majority of patients suffering from anaemia
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due to malignant disease may benefit from treatment with 
EPO.
HGFs were developed with the idea of revolutionising 
cancer therapy by reducing side-effects of cytotoxic agents 
and thus allowing an increment of cytotoxic dose per time 
unit. Furthermore  ^ even more ambitious approaches were 
investigated, e.g, the induction of haematopoiesis in primary 
bone marrow disorders, or using growth factors to trigger 
resting myeloid cells into cell cycle, thus making them more 
amenable to cytoreductive therapy. After almost one decade 
of clinical research, there is no doubt that several of the initial 
hopes have been fulfilled but that many questions remain 
unanswered.
When given in the recommended dosage., HGFs are rela­
tively safe drugs with limited toxicities. HGFs can be self­
injected subcutaneously by the patient. However, HGFs are 
expensive and their non-critical application may contribute to
s
the economical burden of our health care systems.
In recent years, numerous publications have described the 
biology, clinical use and cost-effectiveness of HGFs. This 
review aims to update current knowledge of clinical HGF 
research from a European perspective. In order to address 
these questions and to provide haemato-oncologists with an 
update for clinical application of the myeloid growth factors 
and EPO, the EORTC Biological Therapeutics Development 
Group (BTDG) convened a meeting of experts. This meeting 
was supported by a BIOMED grant of the European Com­
mission (Organization of preclinical and clinical research on 
anticancer therapy with biological response modifiers  ^ No.
BMH1-CT94-1587).
The goal of our report was not to define strict guidelines 
but to give an overview of the indications, for which HGFs 
are authorised or have been used in clinical trials in the var­
ious European countries and describes recommendations for 
clinical indications based on the review of data from con­
trolled clinical trials.
It must be emphasised that clinical application of a 
haematopoietic growth factor will always depend on the
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physician’s judgement with respect to the individual patient 
and the clinical situation. However, our update on clinical 
HGF research may contribute to decision-making by the 
responsible physician, providing sound information on the 
currently available data surrounding still unresolved ques­
tions.
CLINICAL APPLICATION OF ERYTHROPOIETIN 
IN CHRONIC ANAEMIA OF CANCER
Recombinant human erythropoietin (EPO) is the main 
stimulant of erythropoiesis. It exerts its maximal activity at 
the level of the more differentiated erythroid progenitor and 
precursor cells [5] by enhancing proliferation, inhibiting 
ap op to sis, and stimulating haemoglobin synthesis, as well as 
differentiation of red blood cells. It is produced in response to 
tissue hypoxia, mainly (85-90%) by renal tubular interstitial 
cells [6] and to a minor degree also by liver and bone marrow 
(BM) macrophages [7],
Red cell transfusion carries the risk of transmission of 
infections as well as transfusion reactions. Administration of 
EPO has convincingly been shown to increase haematocrit 
and decrease transfusion requirement in 40-70% of patients 
with chronic anaemia of cancer [8,9]. It also prevents or 
ameliorates anaemia in patients undergoing chemotherapy 
with or without cisplatin [8, 10] and improves haemoglobin 
levels in HIV infected patients experiencing anaemia while 
receiving zidovudine treatment [11]. EPO reduces red cell 
transfusion requirements in patients undergoing allogeneic 
bone marrow transplantation [12] but not in those subjected 
to transplantation of autologous bone marrow or peripheral 
blood stem cells. EPO administration also appears to be a 
safe and effective method of increasing red cell mass during 
radiation therapy [13,14],
The starting dose applied in most studies in patients with 
anaemia of cancer or chemotherapy-induced anaemia or for 
zidovudine-associated anaemia in AIDS patients is 150U/kg, 
3x/week. In case of insufficient response, this dose may be 
extended up to 300 U/kg or even higher.
The benefits to patients who are responsive to EPO are not 
only normalisation of anaemia and reduction or prevention of 
transfusion dependency but also a substantial improvement 
of physical activity, performance status and subjective sense 
of well-being, i.e. a general improvement in quality of life 
[15]. In one study, a significantly longer survival time was 
found in responders to EPO treatment as compared to non­
responders [16], In spite of this observation, it is still unclear 
whether the improvement status observed in many respond­
ing patients has any impact on response to cancer treatment, 
thus improving prognosis and survival of the underlying 
malignancy.
Response to EPO treatment is most likely in patients with 
inadequately low levels of endogenous EPO, Usually, an 
absolute endogenous EPO level <100 mU/ml is considered 
inadequate in anaemic cancer patients [7], but calculation of 
the individual patient’s degree of anaemia and EPO level may 
yield more accurate predictions. If the EPO response usually 
seen in patients with an equivalent degree of anaemia caused 
by iron deficiency or blood loss is taken as the 'expected’ level 
(E) and compared to the observed EPO level (O) of that 
patient, the O/E ratio is often decreased in anaemia of 
chronic disease [17]. Approximately 70% of patients with 
chronic anaemia of cancer and an O/E ratio <0.9 have been 
reported to respond to EPO treatment in an ongoing trial. A 
higher predictive accuracy has been provided by a recently 
published algorithm which employs the endogenous EPO 
levels obtained after 2 weeks of treatment and the observed 
change from the baseline haemoglobin level after 2 weeks of 
treatment (Figure 1 ) [18]. With the help of this algorithm, 
response can be predicted with more than 90% accuracy after
2 weeks of EPO treatment, which seems to be clinically useful.
Apart from local skin reactions at the injection site 
observed in a small proportion of patients, EPO treatment is 
very well tolerated by cancer patients. In particular, episodes 
of hypertension, which are a common threat under rhuEPO 
therapy for anaemia of chronic renal failure, occur only rarely 
during EPO treatment of the indications listed above.
For the time being, generally accepted recommendations 
for rhuEPO treatment have not been firmly established in the 
field of haematology/oncology. Randomised trials have shown 
that erythropoietin treatment leads to an increase of haema­
tocrit and decrease of transfusion requirement in anaemic 
cancer patients with and without chemotherapy. Prospective 
trials, however, which include a cost-effectiveness evaluation 
of EPO administration versus red cell transfusion, are unfor­
tunately lacking. Tentatively, the use of rhuEPO may be 
considered in (a) patients with chronic, symptomatic anaemia 
of cancer and low endogenous EPO levels, (b) in facilitating 
autologous blood donation in patients scheduled for elective 
surgery if their requirement of blood transfusions is highly 
probable and (c) in particular for Jehovah’s witnesses and
EPO >100 mU/ml and 
change Hb < +0.5 g/dl
yes no
no response
predictive power 93%
response
predictive power 80%
EPO <100 mU/mf and 
change Hb > +0.5 g/dl
response
predictive power >95%
Figure 1. Prediction of response to rhuEPO  treatm ent in patients with chronic anaem ia of cancer. Hb, haemoglobin.
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Table 1. Generally accepted recommendations for use of recombi­
nant human erythropoietin in the field of haematology!oncology
Indications
Patients with chronic symptomatic anaemia of cancer and low 
endogenous EPO levels with and without chemotherapy
Facilitating autologous blood donation in patients scheduled for 
elective surgery if their requirement of blood transfusions is highly 
probable
Jehovahs witnesses rejecting allogeneic blood, if the necessity of 
blood transfusions is foreseeable
other persons who reject allogeneic bloody if the necessity of 
blood transfusions is foreseeable (Table 1). The prevention of 
chemotherapy induced anaemia in patients who are likely to 
suffer from symptoms of anaemia such as those with pre­
existing cardiovascular disease, coronary heart disease, etc. is 
still debatable as the respective randomised trials have not 
been finalised»
SEVERE APLASTIC ANAEMIA
Bone marrow transplantation is the treatment of choice for 
young patients with severe aplastic anaemia (SAA) and an 
HLA-identical sibling donor. For those patients without a 
suitable donor or beyond the age of 50 years, antilymphocyte 
globulin (ALG) or antithymocyte globulin (ATG) in combi­
nation with or without cyclosporin, androgens or prednisone 
remains the current therapy. Several recombinant human 
HGFs have been used in aplastic anaemia in an attempt to 
increase peripheral blood values, to reduce the risks of com­
plications caused by pancytopenia and eventually to induce a 
sustained multilineage response. Despite many reports, 
results are not yet conclusive.
Erythropoietin
In severe aplastic anaemia (SAA), single cases of response 
to EPO have been published, but no well-designed prospec­
tive studies have been performed, A response was observed in
3 out of 7 patients treated with doses of EPO up to 24 000 U 
twice weekly, but only during treatment with EPO [19]. In 
patients pretreated with ALG or with additional treatment of 
cyclosporin, sustained multilineage responses following ther­
apy with EPO have been published. EPO may reduce the 
need for red cell transfusions in a small subgroup of patients 
with late clonal complications of SAA and low EPO levels
[20].
Myeloid growth factors
Several phase III studies with G- and GM-CSF have been 
published [21-25]. In a prospective randomised placebo- 
controlled multicentre trial [2 1 ], patients with newly diag­
nosed SAA were treated with ALG, followed by GM-CSF or 
placebo. In the GM-CSF group, significantly higher counts 
of neutrophils and monocytes were observed. Only patients 
with some residual marrow function showed an increase in 
neutrophil counts. After withdrawal, leukocyte counts 
declined rapidly and were no longer different in the two study 
roups. The number of days with fever was significantly 
reduced in the GM-CSF group and a trend was observed for 
fewer days on antibiotics in the GM-CSF group» Platelet and 
red cell transfusion requirements were not different for the 
two groups and the overall treatment response and survival
were also identical. Children with SAA treated solely with 
GM-CSF did not show an improvement in the disease nor 
clearance of infections [22]. Thus, GM-CSF without 
immunosuppression should not be given to SAA patients.
Single cases of successful treatment with G-CSF of 
patients with SAA have been reported. Some described a tri­
lineage response following long-term application of G-CSF 
alone or in combination with EPO. Interpretation of these 
data is difficult, as most patients were pretreated with ALG 
and/or cyclosporin. In a larger study, 6 out of 10 children 
with SAA showed an increase in neutrophils and clearance of 
their infections after treatment with G-CSF [23]. In a pilot 
study of the EBMT Working Party for SAA, the use of long­
term G-CSF in combination with ALG, cyclosporin and 
methylprednisolone in 40 patients with newly diagnosed SAA 
led to a trilineage reconstitution in 82% of the patients and 
they became transfusion independent [24]. Another study of 
45 children treated with G-CSF reported an increase in neu­
trophils in 43 of the 45 patients and a trilineage response in 7, 
2 of whom without any other therapy [25].
Conclusion
SAA is not caused by a deficiency of any known HGF. 
Nevertheless, HGFs have been administered in an attempt to 
increase peripheral blood values, to reduce the complications 
of pancytopenia and eventually to alter the course of the dis­
ease. So far, in most patients with SAA treated with G-CSF 
and GM-CSF, a transient increase in neutrophil counts has 
been observed, the extent of the rise being proportional to the 
amount of residual myelopoiesis. Early acting growth factors 
(e.g. IL-3, IL-6 and SCF) have not yet been shown to be 
effective in the treatment of SAA [26-29]. There is no clear 
evidence yet, despite the claims of several case reports, that 
treatment with HGFs have changed the course of the disease. 
In addition, substantial side-effects can be observed with the 
administration of HGF. The currently available recombinant 
human HGFs are interesting tools to investigate regulation of 
haematopoiesis and promising agents to improve outcome of 
patients with SAA. Despite almost a decade of investigation, 
clear answers are lacking. Patients with newly diagnosed SAA 
should not be treated with growth factors outside a clinical 
protocol. Inappropriate use of HGFs could reduce the excel­
lent chance of long-term cure after allogeneic BMT or delay 
administration of effective immunosuppressive therapy. In 
contrast, well-designed clinical trials will allow us to establish 
the role of HGFs and their combination and further improve 
the current results.
MYELODYSPLASTIC SYNDROMES
At present, many studies have been performed with EPO, 
GM-CSF [30-33], G-CSF [34,35] and IL-3 [36] in patients 
with a myelodysplastic syndrome and a low risk of developing 
leukaemia (MDS-LR), either alone [30-35] or in combina­
tion with low-dose Ara-C in MDS at a high risk of developing 
leukaemia (MDS-HR) [37,38].
Erythropoietin
In patients with a low risk of developing leukaemia (MDS- 
LR), the main clinical problem is the dyserythropoietic anae­
mia requiring regular red cell transfusions and finally leading 
to iron overload. The effect of EPO on this anaemia is not 
very favourable. It has been reported that approximately 15- 
20% of the patients respond to dosages of EPO that are
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commonly used in anaemia due to renal disease [39]. 
Administration of very high dosages of EPO in combination 
with one of the myeloid growth factors may improve response 
rates up to almost 50% [40]. Response means transfusion 
independence, not necessarily normalisation of the haemo­
globin content. Although very high dosages of EPO in com­
bination with another HGF may be more promising, financial 
limitations prohibit farther exploration in most centres.
Myeloid growth factors
GM-CSF and G-CSF have been used in Europe and the 
U.S. Neutrophilia, eosinophilia (related to GM-CSF) and 
increases in reticulocyte, lymphocyte and monocyte counts 
have been reported in several phase II and III studies 
[32*38]. These effects are generated at relatively low dosages 
of these HGFs independently of the route of administration. 
A response rate of 70% has been reported in large series of 
patients treated with GM-CSF [32]. The effects of GM-CSF 
on neutrophils were seen within 1 week from the start of the 
administration and disappeared within 4 weeks after discon­
tinuation. Observed side-effects at these low dosages were 
mild. No increased risk of transformation to leukaemia has 
been reported in the MDS-LR series. The effects of G-CSF 
are similar to those described for GM-CSF. Long-term 
administration of low-dose GM-CSF or G-CSF appears to 
be promising as far as haematopoietic activity and side-effects 
are concerned. The effects of GM-CSF or G-CSF on the 
incidence of infection have been evaluated in several phase II 
trials as well as in randomised trials. Results of these trials 
have shown an improved phagocytosis and bacterial killing by 
HGF administration with a positive impact on the incidence 
of infectious episodes [34,37]. Effects of GM-CSF and G- 
CSF on platelet counts and haemoglobin levels are rare. The 
role of IL-3 and IL-6 is unclear, but not very promising. The 
role of HGFs in myelodysplastic syndromes at high risk of 
developing leukaemia is even more unclear. In this settings 
HGFs have been given in phase II and III studies in combi­
nation with low-dose Ara-C or in combination with intensive 
induction chemotherapy courses. All these policies lead to 
haematopoietic improvement in approximately 50% of the 
patients. It is still unclear whether this is the result of the 
cytostatic treatment or due to the combination with one of 
the growth factors G-CSF, GM-CSF or IL-3.
Interleukins
Interleukin-3 has been administered to few patients with 
MDS-LR [38]. Whereas side-effects appeared to be more 
severe (headache, fever, chills, skin reactions), neutrophil 
responses were less prominent than after G/GM-CSF 
administration. Platelet counts or reticulocyte numbers 
increased in only a small number of patients.
The effect of IL-6 on platelet counts is disputable. One 
study in the United States [41] of recombinant human inter­
leukin-6 in patients with myelodysplastic syndromes and 
thrombocytopenia showed an increase in platelet numbers. 
Side-effects including fever, chills and flu-like symptoms were 
already present at very low dosages.
Conclusion
The role of myeloid HGFs in myelodysplastic syndromes 
at low risk of developing leukaemia is rather disappointing. 
GM-CSF and G-CSF cause an increase of neutrophils and 
their administration may only be indicated in patients with
repetitive infectious episodes and neutropenia. Since most 
results in patients with acute leukaemia treated with chemo­
therapy and HGFs did not show an additional effect of the 
HGF on treatment response, it is not very likely that a posi­
tive effect of G-CSF, GM-CSF or IL-3 would be expected in 
patients with high-risk MDS treated in a similar way.
ACUTE LEUKAEMIA
In acute myeloid leukaemia (AML), leukaemic blast cells 
express receptors for HGFs, with interindividual variability in 
number, type and affinity of receptors [42]. Treatment of 
AML with HGFs has theoretically two kinds of potential 
therapeutic effects. First, they can recruit leukaemic cells into 
cycle, thus enhancing their sensibility to chemotherapy [43- 
45]. Therefore, their administration before and during 
chemotherapy may lead to increased leukaemic cell kill Sec­
ond, when administered after the cytotoxic courses, they may 
stimulate the normal haematopoietic progenitors, thus accel­
erating haematopoietic recovery and reducing the morbidity 
and eventually mortality from infection. The presence of 
receptors for HGFs in both normal and leukaemic cells could 
challenge these therapeutic effects by two possible adverse 
consequences: ( 1 ) when given before and during chemo­
therapy, recruitment of normal pluripotent stem cells in cycle 
may increase their fraction exposed to cycle-dependent cyto­
toxic drugs and results in more prolonged marrow aplasia; 
(2) when administered after the chemotherapy courses, 
stimulation of residual leukaemic clones may occur, with a 
risk of resistance to induction treatment or early relapse. 
Whether given during or after the induction courses, the 
HGFs may prevent chemotherapy-induced apoptosis of leu­
kaemic cells [46,47].
HGFs in acute myeloblastic leukaemia
Several pilot studies combining GM-CSF or G-CSF with 
chemotherapy during induction treatment of AML indicated 
that HGFs may accelerate the recovery of neutrophils, and/or 
result in a higher complete remission (CR) rate, when com­
pared to historical controls [48-51]. Results of randomised 
multicentre trials using GM-CSF or G-CSF have recently 
been published [52-59] (Table 2). Unfortunately, the designs 
were quite different from one study to another, thus making 
comparisons difficult. In addition, few attempts have been 
made to assess separately the two biological effects: the 
priming effects by administration before and during the 
chemotherapy courses, and the acceleration of normal hae­
matopoietic recovery by administration after chemotherapy. 
Recruitment of leukaemic cells into cycle has been observed 
by cell kinetics methods in some studies [44]. The optimum 
dose schedules of HGFs for priming of the leukaemic cells 
remains largely unknown. The administration of GM-CSF 
for several days before the start of chemotherapy may also 
induce a hyperleukocytosis with eventually pulmonary infil­
trates [60]. An early start of GM-CSF, 4-7 days before 
induction chemotherapy, might explain the relatively low CR 
rate in patients reported by Estey and associates when com­
pared to a group of matched historical controls [61].
A significantly shorter duration of neutropenia was 
observed in some studies with GM-CSF [55] or G-CSF 
[52,57], administered after the induction chemotherapy 
courses. This slightly accelerated recovery did not result in a 
significant reduction of the rate of documented infections or 
mortality during hypoplasia. Only the ECOG Cooperative
1736 A J .  Croockewit et al
chemotherapy for AML
References HGF used Schedule of HGF in 
relation to chemotherapy (day = 0)
Number of Complete remission in Rate of ANC 
patients HGF/placebo (%) recovery
Ohno [52] G-CSF day 2  until recovery
Witz [54] GM-CSF day 0 until recovery
Stone [55] GM-CSF day 8 until recovery
Drombret [56] G-CSF day 8 until day 28
Rowe [57] GM-CSF day 1 1  until recovery
Heil [58] GM-CSF day 2  until recovery
Zittoun [59] GM-CSF day 1 until day 7/day 28 (factorial 2x2)
108* 50/36 ++
163 63/67 NS
347 49/53 NS
173*1* 70/47 ++Î
118 61/46 ++
80 81/79 NS
102 47/74 NS
ANC> absolute neutrophil count; AML, acute myeloid leukaemia. *AML and acute lymphoblastic leukaemia, relapse or refractory; H G F, 
haematopoietic growth factor; NS, difference not significant, f  Elderly AML. £No difference for frequency and severity of infections.
study showed a significant decrease of grade 4-5 infections, 
with a trend to a lower therapy-related mortality and a higher 
CR rate [55]. The reasons for this discrepancy with the other 
studies on GM-CSF [54,56-58] remain to be explored. The 
results of a randomised study of the EORTC Leukemia 
Cooperative Group [59] are a matter of concern. In this 
study3 using a 2 x 2 factorial design, the CR rate was signifi­
cantly lower in AML patients who received GM-CSF after 
the chemotherapy courses when compared to the control 
group. By contrast, there was no difference in the CR rate 
whether or not patients received GM-CSF before and during 
the chemotherapy courses. However, positive results were 
published in favour of a combination with G-CSF by Dom- 
bret and colleagues who used this HGF in elderly AML 
patients from day 9 until day 28 or earlier in case of haema­
topoietic recovery [56]. These authors observed a signifi­
cantly higher CR rate in patients receiving G-CSF, without 
reduction of the mortality rate from infection. The higher CR 
rate was related to a lower resistance of leukaemia, especially 
in patients with adverse prognostic factors. These results 
raised the hypothesis of an antileukaemic effect of G-CSF by 
stimulation of terminal differentiation of the residual leukae- 
mic cells. If confirmed, they indicate positive biological 
effects of G-CSF in patients with AML.
HGFs in acute lymphoblastic leukaemia
In acute lymphoblastic leukaemia (ALL), the use of G- 
CSF, and, eventually, GM-CSF, might be beneficial during 
induction and consolidation of ALT,. Although functional G- 
CSF and GM-CSF receptors have been observed sometimes 
in ALL, especially in the biphenotypic acute leukaemias and 
Phi-positive ALL [62], there is generally no evidence of 
growth stimulation of leukaemic lymphoblasts by G-CSF, 
either in vitro [63] or in clinical trials [64]. In a recent ran­
domised study of the German group, G-CSF, administered 
during the second part of the induction course, significantly 
reduced the duration of neutropenia, with less severe bac­
terial infections and earlier completion of the induction 
programme [65]. Opportunistic infections—especially asper­
gillosis—are a major concern during the treatment of ALL, 
probably due to intensification of chemotherapy and conco­
mitant treatment with immunosuppressive agents. Systematic 
use of HGFs along with other prophylactic measures may 
reduce the rate of opportunistic infections.
Conclusion
In AML, further randomised studies comparing the various 
HGFs at different doses schedules are warranted. Outside 
such controlled prospective studies, the use of HGFs should
be avoided in AML, at least during the induction period, thus 
supporting the recent recommendations of an expert panel of 
the American Society of Clinical Oncology updated in 1996 
[66,67]. In ALL, these restrictions are more relative and 
flexible.
PERIPHERAL STEM CELL TRANSPLANTATION 
IN HAEMATOLOGY AND ONCOLOGY
A somewhat unanticipated benefit from the introduction of 
HGFs was the discovery that they mobilised haematopoietic 
progenitors from the marrow into the peripheral blood 
stream. These cells can be harvested by one of several apher- 
esis procedure (s) and cryopreserved to be reinfused after 
high-dose therapy. In the last 5 years, peripheral blood is 
rapidly replacing bone marrow as the preferred source of 
stem cells for autologous transplantation after myeloablative 
therapy. The most striking finding of PBSC transplantation is 
the faster trilineage haematological reconstitution of hemato- 
poiesis after high-dose chemotherapy as compared to ABMT 
[68]. In a randomised study [68] comparing autologous BM 
and PBSC transplantation in lymphoma patients, both time 
to platelet recovery and time to neutrophil recovery above 
was significantly reduced in the PBSC transplantation group. 
In addition, the relatively low burden of the harvest proce­
dure may explain the increased popularity of PBSC. Fur­
thermore, total costs of PBPC autografting are lower than 
those of ABMT [69], Peripheral blood stem cells can be 
mobilised by chemotherapy [70-72], chemotherapy followed 
by HGFs [73-75] and HGFs alone [76-79]. Despite the 
increasing knowledge of progenitor-stroma interaction, the 
mechanisms of stem cell mobilisation remain undefined. 
Other mechanisms beside proliferation seem to be involved. 
In primates, antibodies to the adhesion molecule VLA-4 
cause a release of stem cells into the peripheral blood [80]. 
The release of stem cells into the blood may be the result of a 
perturbation of the adhesive interactions between these cells 
and the marrow stroma that, in steady-state conditions, serve 
to restrict haematopoietic stem cells to the bone marrow and 
keep them in a resting state [81]. To quantitate PBSC, the 
number of granulocyte-macrophage colony-forming units 
(CFU-GM) and the number of CD34 positive cells may be 
used. The CD34 assay is a more reproducible assay and 
probably also more reliable. The threshold dose of CD34 
positive cells necessary for prompt engraftment is approxi­
mately 2-5 x 106/kg, depending on the amount and duration 
of previous chemotherapy before transplantation [82-85].
The exact function of CD34 is not known. Three pos­
sible functions of this sialomucin may involve adhesion 
[86], signalling [87] or growth-factor presentation. Recent
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experiments [88] showed that in mice lacking CD34, hae- 
matopoiesis was delayed in developing embryoid bodies. 
CD34-deficient haematopoietic progenitors were unable to 
expand in liquid cultures in response to HGFs. These data 
indicate that CD34 is involved in the proliferation and/or 
maintenance of the haematopoietic progenitor cells in 
embryos and adults.
PBSC mobilisation by HGFs
Several HGFs including G-CSF [76, 79, 89,90], GM-CSF 
[77,91,92] and other HGFs such as IL-3, IL-6, EPO, stem 
cell factor, PIXY 321 have been used to mobilise stem cells 
into the blood. The best studied single mobilising agents are 
G-CSF and GM-CSF. Administration of G-CSF [89] and 
GM-CSF [91] induce an up to 100-fold increase of circu- 
lating stem cells in patients with various malignancies. Chao 
[93] reported that patients treated with G-CSF mobilised 
PBSC had a more rapid engraftment than patients receiving 
non-G-CSF mobilised PBSC. For G-CSF, a clear dose- 
response effect could be shown for dosages of 5, 10 and 
24|ig/kg/day [76,94]. The same effect was reported for the 
use of GM-CSF at dosages of 125 and 250 jag/m2/day [77]. 
In most circumstances, a dosage of 5 j-ig/kg is adequate for 
both G- and GM-CSF. Combinations of HGFs are also 
effective in mobilising PBSC. Theoretically, cytokines that 
stimulate early progenitors, such as IL-3, SCF and the FLT3 
ligand, may expand the pool of progenitors responsive to the 
late acting haematopoietic growth factors. When given as a 
sole agent, these early acting cytokines have only limited stem 
cell mobilising potential, but when given in combination* 
e.g. IL-3+GM-CSF [95], IL-3+G-CSF [96], SCF+G-CSF 
[97] synergistic effects on PBSC mobilisation have been 
observed. Whether these combinations of HGFs offer clini­
cally relevant advantages over the use of G-CSF or GM- 
CSF alone has not yet been demonstrated.
The approach of using a combination of chemotherapy 
and growth factors was first reported by Gianni and col­
leagues, who treated patients with cyclophosphamide and 
GM-CSF [98]. Other agents such as etoposide and cytara- 
bine combined with HGFs are similarly effective [99]. The 
combination of chemotherapy and HGFs is more effective in 
mobilisation of PBSC than chemotherapy alone 
[76,98,100,101]. Brugger and associates [95] showed that 
GM-CSF plus IL-3 in addition to chemotherapy further 
increased PBSC mobilisation as compared to chemotherapy 
alone or chemotherapy with GM-CSF.
Stem cell mobilisation in allogeneic healthy donors is also 
possible by administration of G-CSF or GM-CSF alone. 
Preliminary data suggest that rapid and sustained haemato­
poietic engraftment without a dramatically increased inci­
dence of acute graft versus host disease occurs despite a 
higher number of donor T-cells infused [79,102-104].
Use of HGFs after PBSC infusion
Spitzer [105] has shown that administration of a combina­
tion of G-CSF and GM-CSF after PBSC infusion shortens 
the duration of granulocytopenia by several days, but it has 
no influence on the duration of thrombocytopenia. Others 
[106,107] have shown that G-CSF failed to improve hae­
matopoietic reconstitution following myeloablative chemo­
therapy and PBSC transplantation. Therefore, the clinical 
benefit of HGF administration has not yet been demonstra­
ted and may depend on individual clinical circumstances.
Currently, phase III randomised placebo-controlled trials are 
underway to determine the clinical benefit, optimal dosage and 
schedule of HGF administration after PBSC transplantation.
Conclusions
G-CSF and GM-CSF should be considered equally effec­
tive in mobilising short- and long-term repopulating stem 
cells to the peripheral blood to be used for autologous trans­
plantation- G-CSF and GM-CSF in combination with che­
motherapy are more effective than chemotherapy alone in 
mobilising PBSC. The clinical benefit of HGF administration 
after PBSC infusion has not yet been demonstrated. Until 
sound data are available, after PBSC transplantation HGFs 
cannot be recommended outside clinical protocols,
PROPHYLACTIC AND THERAPEUTIC USE
Neutropenia and infection are the most important dose- 
limiting toxicities for the majority of chemotherapy regimens. 
The risk of infection is directly related to the duration and to 
the degree of neutropenia [108]. The magnitude of myelo- 
suppression depends on the type and intensity of chemo­
therapy. The administration of HGFs produces a rapid and 
substantial increase in peripheral blood neutrophil count by 
amplifying neutrophil production and decreasing the time to 
release of mature neutrophils [104]. In this way, the use of 
HGFs may reduce the duration of chemotherapy-related 
neutropenia and the risk of infection. However, few combi­
nation chemotherapy regimens induce more than a 40% rate 
of grade 4 myelosuppression, which was the criterium for use 
of HGFs by the expert panel of the American Society of 
Clinical Oncology [66,67,110]. Furthermore, the infection- 
related mortality due to febrile neutropenia is low, ranging 
from 0 to 7%. The duration of hospitalisation for febrile 
neutropenia can exceed 1 week with consequent reduction in 
terms of quality of life for the patients, and in delay or dose 
reduction for subsequent chemotherapy. It might be justified 
to use HGFs with the intent to improve patients quality of 
life, to reduce the hospital cost and to improve the chemo­
therapy delivery.
Primary prophylaxis
Three prospective, randomised placebo-controlled trials 
analysed the impact of HGFs on febrile neutropenia inci­
dence during standard-dose chemotherapy. Two of these 
trials used chemotherapy consisting of cyclophosphamide, 
doxorubicin and etoposide (CDE) in patients with small cell 
lung cancer (SCLC) and one used cyclophosphamide, dox­
orubicin, vincristine, bleomycine, etoposide and prednisolone 
(VAPEC-B) in patients with NH L [111-113]. In all these 
trials, neutrophil recovery occurred faster with HGF use and 
the relative incidence of febrile neutropenia was reduced by 
approximately 50%. In the SCLC trials, HGF administration 
was associated with a decrease of antibiotic use and hospi­
talisation. Pettengell and associates randomised 80 patients 
with NHL to receive VAPEC-B chemotherapy with or with­
out G-CSF. Patients randomised to receive G-CSF achieved 
a greater dose intensity than control patients, but this did not 
result in significant differences in drug toxicity (other than 
neutropenia), intravenous antibiotic usage or hospitalisation 
between the two groups. These three randomised studies did 
not report a difference in infection-related mortality, tumour 
response rate and patient survival between HGF and pla­
cebo-treated subjects.
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Bajorin and associates [114] recently published the results 
of a multicentre randomised study on patients with advanced 
or relapsed germ cell tumour receiving conventional dose 
ifosfamide plus cisplatin in combination with etoposide or 
vinblastine. One hundred and eight patients were enroled and 
randomised to receive GM-CSF after chemotherapy in order 
to assess the impact of GM-CSF on the severity of neutro­
penia and the incidence of infectious complications due to 
the treatment planned. The use of GM-CSF was associated 
with a clinically significant reduction in the incidence of 
infections only during the first cycle of chemotherapy* while 
this benefit was not observed during subsequent cycles. The 
cost benefit of HGF prophylactic use seemed related to the 
risk of hospitalisation* to the rate of risk reduction and finally 
to the costs of the single institution [115*116]. With these 
assumptions* the use of HGFs was felt to be justified only if 
the baseline risk of febrile neutropenia exceeded more than 
40% and the cost of hospitalisation in single institutions was 
considered high. In summary* the use of HGFs as primary 
prophylaxis is not recommended for all patients receiving the 
first course of standard chemotherapy (Figure 2). In those 
patients with known poor bone marrow tolerance* HGF 
prophylaxis may be considered upfront.
Secondary prophylaxis 
For secondary prophylaxis* it is appropriate to prescribe 
HGFs for those patients who have had infections or neutro­
penia (ANC<1000 cells/jiL) exceeding 7 days during the 
first course of chemotherapy (Figure 3), In those patients* the 
subsequent full-dose treatment could expose them to life- 
threatening complications or alternatively if the dose was to 
be reduced it would lead to a decrease in expected long-term 
success rates. This approach is recommended when the aim 
of treatment is curative such as in germ cell cancers or lym­
phomas [1 10 *68].
Febrile neutropenia 
Applying HGFs only in the case of infection during neu­
tropenia would reduce the number of patients exposed to 
HGFs and might restrict the costs of treatment. Six rando­
mised studies using HGFs in patients with febrile neutrope­
nia have been conducted (Table 3) [117-122]. The studies 
differed with respect to patient categories and treatment pro­
tocols. In three studies a significant advantage in terms of 
neutropenic fever was observed for GM-CSF or G-CSF 
[118-120]. In none of the studies a significant difference was 
found in infection-related mortality between HGF and pla­
cebo-treated patients. Therefore* for the majority of patients 
with febrile neutropenia* the available data do not clearly 
support the routine use of HGFs as adjuncts to antibiotic 
therapy. The results of the studies do not exclude that a sub­
group of patients* e.g. with pneumonia* sepsis syndrome or 
fungal infection* may benefit from the use of HGFs.
Afebrile neutropenia
The use of HGFs in afebrile neutropenic patients has been 
investigated in at least one placebo-controlled randomised 
trial [123] in several tumour types and lymphomas. Although 
it shortened the duration of severe chemotherapy-induced 
neutropenia* it had no impact on clinical outcome.
COMPARATIVE DIFFERENCES IN THE 
CLINICAL SPECTRA OF G-CSF AND GM-CSF
While both factors have been shown to ameliorate the 
complications of neutropenia* there are potentially important 
clinical differences in their haematopoietic spectrum* in their 
toxicity and in the potential they possess to induce other 
biological effects.
Preclinical and early clinical studies indicated that the 
activity of G-CSF was essentially confined to neutrophils and 
their precursors [124* 125]. It was therefore anticipated that
Is the chemotherapy regimen 
associated with a >40% risk 
of febrile neutropenia?
Yes No
Dose reduction
if appropriatet
Does the patient have 
poor BM tolerance*
t
Consider chemotherapy with 
HGF support in 1 st and 
subsequent cycles
Yes No
Administer chemotherapy 
without HGF support
Figure 2* Administration of myeloid HGFs in the primary prevention of febrile neutropenia. *BM heavily infiltrated by malig- 
nancy, myelodysplasia or previously treated by chemotherapy or radiography. fDose reduction may be appropriate if  it does not
compromise treatment goal.
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Did the patient tolerate the 
chemotherapy without severe 
myelotoxicity during the 
previous cycle?
No Yes
Did the patient experience 
febrile neutropenia?
Yes No
Will dose reduction 
potentially 
compromise 
treatment goal?
Dose reduction 
if appropriate
Yes No
t t
Administer chemotherapy 
with HGF support in
subsequent cycles
Dose reduction 
as required
I
Continue chemotherapy 
cycles as indicated
Figure 3. Administration of myeloid HGFs in the secondary prevention of febrile neutropenia.
Table 3. Number of observed episodes of febrile neutropenia and infectious mortality in studies using H G F in febrile neutropenia
References H G F used N um ber of observed patients 
with febrile neutropenia 
H G F  placebo
Infectious mortality 
HGF (%) placebo (%) P
Biesma [117] GM -CSF 15 15 3 0 ns
Riikonen [118] GM -CSF 28 30 0 0 ns
M aher [119] G-CSF 109 107 7 3 ns
Mayordomo* [120] G-CSF and G M -CSF 39 and 39 43 7 and 3 3 ns
Anaissief [121] GM -CSF 50 50 2 6 ns
Vellenga [1 2 2 ] GM -CSF 65 69 1 2 ns
Collective analysis 345 314 4 2 ns
4
*Study with three arms (respectively G-CSF, G M -C SF and placebo), f  Study without placebo control, nsj not significant.
the less lineage-restricted activity of GM-CSF might offer 
clinical advantages over G-CSFs especially in terms of anti­
microbial activity. A review of the many trials in which these 
agents have been used in patients receiving cytotoxic chemo­
therapy does not seem to confirm such an advantage 
[126, 1 27]. Also in prospective trials in which patients with 
febrile [128] or non-febrile neutropenia [129] were randomly 
assigned to receive either G-CSF or GM-CSF3 there has been 
no difference of efficacy. There have also been suggestions
that GM-CSF might have a clinically meaningful thrombo- 
poietic effect  ^but confirmation is lacking [130].
Another potentially important difference in the activity of 
these agents concerns their effects on the kinetics of haema­
topoietic progenitors. Both factors induce progenitors into 
cycle3 but following cessation of GM-CSF3 a phase of pro­
found kinetic quiescence occurs during which the cells may 
be less vulnerable to chemotherapy [131]. The wider spec­
trum of biological activity of GM-CSF compared to G-CSF
1740 A J .  Croockewit et al
raised the possibility that GM-CSF might have other mean­
ingful clinical activities. There has been particular interest in 
the possibility that this agent might exert an independent 
antitumour effect. No such anticancer activity has been con­
firmed in the trials which have been performed [66]. The 
local administration of GM-CSF, but not G-CSF, was also 
shown to promote wound healing in a rat model [132],
G-CSF and GM-CSF exist in a glycosylated and a non­
glycosylated form. Although the glycosylated and non-glyco- 
sylated forms of G-CSF have been shown to differ biologi­
cally in vitro [133] 5 so far no clinical study has shown a 
relevant difference between the use of glycosylated versus 
non-glycosylated products.
Toxicity
When compared to other drugs in use in oncology, both 
GM-CSF and G-CSF have quite favourable toxicity profiles 
[126,134]. G-CSF is a particularly well-tolerated agent. The 
only side-effect which has been reported frequently is bone 
pain with an incidence of 14% in patients treated with 
chemotherapy to 80% in donors for allogeneic transplantation 
[135-137]. Children who receive G-CSF for primary neu­
tropenic disorders occasionally develop splenomegaly which 
may result in thrombocytopenia. Rarely, acute flare-ups of 
pre-existing inflammatory diseases can occur, as can Sweet’s 
syndrome or acute neutrophilic dermatosis [138]. The pat­
tern of toxicity of GM-CSF is more typical of that which has 
been reported for the administration of other cytokines, with 
fever and chills occurring relatively often and with occasional 
patients (especially at higher doses and with intravenous 
administration) developing pleural and pericardial effusions
[139]. However, in one prospective randomised trial in which 
the administration of G-CSF was compared to that of GM- 
CSF, no differences in toxicity were reported [129].
THE IMPORTANCE OF DOSE IN CANCER
CHEMOTHERAPY
Since many conventional chemotherapy regimens are given 
at, or close to, the maximum tolerated dose, the scope for 
dose escalation is limited by increased toxicity. The most 
common obstacle to more effective chemotherapy delivery is 
severe myelosuppression. Attempts to escalate the dose 
intensity of chemotherapy require effective haematopoietic 
support to ensure prompt restoration of normal haematopoi- 
esis. Previously this has only been possible with bone marrow 
transplantation (BMT) restricted to specialised hospital 
units. The introduction of recombinant HGFs and in par­
ticular recombinant G-CSF and GM-CSF has provided hae- 
matologists and oncologists with powerful tools to 
manipulate haematopoiesis and thus be able to enhance the 
delivery of chemotherapy at standard or escalated doses
[140]. It is difficult to predict whether increased dose inten­
sity will produce better results [136].
Prospective randomised trials of dose intensity were 
obviously limited by myelotoxicity until the advent of recom­
binant HGFs. Nevertheless, at least two different questions 
can be asked in this context: (a) How does a reduction in 
standard-dose chemotherapy affect response rate and survi­
val? (b) How does an increase in the dose of chemotherapy 
affect response rate and survival?
The first question is concerned with the concept of a 
‘threshold5, or minimum effective dose. It is common practice 
in oncology to delay treatment or reduce dose after chemo­
therapy-induced toxicity, but no clinical trials have convin­
cingly demonstrated that this option is without risk. Probably 
the first solid evidence for the existence of such a 'threshold1 
in the adjuvant treatment of breast cancer has come from a 
recent Cancer and Leukemia Group B (CALBG) study that 
enroled 1572 patients with stage II, node-positive breast 
cancer [141]. All patients received adjuvant CAF (cyclo­
phosphamide, doxorubicin and 5-FU) chemotherapy every 4 
weeks at one of three dose rates (mg/m2) high (600/60/600), 
moderate (400/40/400) and low (300/30/300). Patients on 
the high-dose arm and the low-dose arm were treated with
4 cycles (4 months) of chemotherapy, and the dose of each 
drug given in the low-dose arm was exactly half that given to 
those in the high-dose arm. As a result* the cumulative dose 
of cyclophosphamide, doxorubicin and 5-fluorouracil given 
to patients in the low-dose arm was half that given to those in 
the high-dose arm. In contrast, patients randomised to the 
mo derat e-dose arm of the study received six cycles of che­
motherapy, but the dose of cyclophosphamide, doxorubicin 
and 5-FU on each cycle was two-thirds that given to patients 
on the high-dose arm. As a result, the cumulative doses of 
each drug given to patients on the moderate- and high-dose 
arms were identical, but the rate at which the drugs were 
administered was faster for patients in the high-dose arm. At 
a median follow-up of 3.4 years, disease-free survival and 
overall survival were significantly better in the high-dose 
group compared with the low-dose group, although toxicity 
was also greater.
The second question that should be addressed by pro­
spective studies is the one currently attracting more attention: 
does an increase in the dose of chemotherapy affect response 
rate and, above all, survival? Most oncologists feel that only if 
a clear benefit in terms of disease-free survival or overall sur­
vival can be proven, then these toxic and expensive therapies 
can be justified.
Haematological malignancies
High-dose chemotherapy seems to be justified in acute 
myeloid leukaemias (in first or second remission). For exam­
ple, in a large multicentric randomised protocol of the 
EORTC and GIMEMA Cooperative Groups [142], designed 
to compare prospectively conventional intensive chemo­
therapy versus consolidation with autologous BMT (ABMT) 
or allogeneic BMT (alio BMT), at a median follow-up of 3 
years, the results appeared satisfactory, with a disease-free 
survival (DFS) of the intensive chemotherapy arm (29% at 4 
years) at least equivalent to the previous studies with less 
intensive regimens, and a DFS in the allo-BMT and ABMT 
of 54% and 49%, respectively. The two BMT arms gave sig­
nificantly better results than the intensive chemotherapy arm 
(P=0.04). The main reason for failure was relapse in both 
the ABMT and chemotherapy arm, while treatment-related 
mortality was higher in the allo-BMT arm.
Mounting evidence (including preliminary data from ran­
domised studies) indicate that ABMT should be performed 
in relapsed chemosensitive Hodgkin’s disease and NHL, or 
even up-front as consolidation of first remission in poor- 
prognosis NHL, and in some acute lymphoblastic leukaemias 
with poor prognosis features. For example, with conventional 
CHOP-like chemotherapy regimens or more intensive weekly 
regimens, the five-year survival rate for intermediate- and 
high-grade NHLs, a classical model of a chemosensitive and 
chemo curable disease, is only approximately 50%. Moreover,
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the 10 % of patients who fail to respond to initial therapy, or 
the 30% who relapse after complete remission, have an 
extremely poor prognosis with a DFS usually less than 10% 
at 3 years. Philip and associates [143] have recently presented 
the final analysis of a randomised study with 216 patients 
with relapsed intermediate or high-grade NHL. All patients 
in this multicentric study had previously a complete response 
(CR) to a doxorubicin-containing regimen, no neurological 
and bone marrow involvement and no major organ dysfunc­
tion. All patients received two courses of a semi-intensive 
regimen (DHAP chemotherapy) and 109 patients (with CR 
or a very good partial response) were randomised to receive 
either four further courses of DHAP plus radiotherapy to 
involved sites or radiotherapy plus high-dose chemotherapy 
(BEAC) with ABMT rescue. No difference in terms of prog­
nostic factors at inclusion were observed between the two 
groups (LDH level, tumour size, histological groups). Four 
toxic deaths were observed in the BMT arm (out of 50 
patients actually transplanted) and none in the chemotherapy 
arm. All patients were included in the final analysis and DFS 
was 46% in the BMT arm versus only 12 % in the control arm 
at 5 years follow-up. Similarly* differences were also signifi­
cant in terms of overall survival (OS): 53% versus 32% at 5 
years. The authors concluded that high-dose chemotherapy 
and BMT should now be regarded as standard therapy in 
sensitive relapse of NHLs, but BMT is not able to salvage 
chemotherapy failures at subsequent relapse.
In multiple myeloma patients, the question of whether 
early intensive therapy with autologous stem cell support 
offers advantage over conventional treatment has been 
recently addressed by Attal and collegues [144]. In a 
randomised trial, melphalan 140 mg/m2 plus TBI 800 cGy 
was compared with standard vincristine/melphalan/cyclo- 
phosphamide/prednisone-vincristine/carmustine/doxorubicin/ 
prednisone (VMCP-VBAP) in 200 patients. The high-dose 
arm produced a higher complete response rate (2 2 % versus 
5%), longer EFS (27 months versus 18 months) and OS 
(probability of 5 year survival of 52% versus 1 2 %), respectively.
Solid tumours
In numerical terms, the impact of high-dose chemotherapy 
is likely to be more important for some chemosensitive solid 
tumours and, in particular, for cancer of the breast. Follow­
ing some pilot studies, several randomised studies are ongo­
ing for 10 or more positive axillary lymph nodes and in some 
studies also patients with more than 4 to 10 positive lymph- 
nodes are included.
Five year follow-up is now available from at least two non­
randomised studies: (1) Peters and associates [145], at Duke 
University, North Carolina, U.S.A. treated 85 patients with 
10  or more axillary lymph nodes with adjuvant high-dose 
cyclophosphamide, cisplatin and carmustine (CPB) and 
autologous BMT after CAF adjuvant chemotherapy. The 
median age was 38 years, the median number of involved 
axillary lymph nodes was 14 and therapy-related mortality 
was 12%. Although the risks of comparison to historical 
controls have been discussed, the five-year DFS in this series 
was 71% (95% confidence interval: 53-84%), compared to 
only 28-34% in historical published studies. Differences were 
also statistically significant in terms of overall survival.
In a similar study, but using a novel high-dose sequential 
combination chemotherapy (HDS), Gianni and associates 
[146] reported only 1 procedure-related death (out of 67
patients) and a DFS at 5 years of 56% (overall survival 78%) 
versus 33-41% in the best historical series (overall survival 
60%). If only patients with 10-15 axillary nodes were 
analysed and patients with more advanced disease were 
excluded, then the figures became 64% for DFS and 83% for
OS in the HDS group.
Other potential but still speculative indications for dose­
intensive chemotherapies in solid tumours and haematologi- 
cal malignancies are currently being tested in the clinic and 
include chronic myeloid leukaemia (CML) [147] and chronic 
lymphocytic leukaemia (CLL) in young patients [148], 
relapsed or poor-prognosis germ-cell cancers [149], several 
paediatric tumours (including stage IV neuroblastomas)
[150], advanced epithelial ovarian cancer in young women
[151], advanced melanoma and brain tumours. For some 
common epithelial cancers, like colorectal cancer, response 
rates but not survival have been increased by high-dose 
chemotherapy [152], Similarly, more than 200 patients world­
wide with limited stage small cell lung cancer (an example of 
a chemosensitive but not usually chemocurable tumour) have 
received high-dose chemotherapy with autologous BMT, but 
to date, median disease-free survival and overall survival have 
been comparable to those associated with standard chemo­
therapy [153]. Low-grade NHL is another example of an 
initially chemosensitive disease, where high-dose chemo­
therapy has not yet been shown to definitely improve survival 
[154].
For the time being, it seems reasonable to conclude on 
these grounds that HGFs may support the delivery of full- 
dose chemotherapy in chemosensitive malignancies and may 
prevent suboptimal treatment due to underdosing. This 
ought to be particularly important if the main objective is 
cure or long-term survival. Currently, use of these growth 
factors (with or without cellular support) in the context of 
high-dose chemotherapy should be limited to experimental 
protocols. This is also the opinion of the Accreditation Sub­
committee of the European Group for Blood and Marrow 
Transplantation (EBMT) [155].
CONCLUSION
This review deals with the results of clinical studies with 
HGFs that have been registered for clinical application: ery­
thropoietin (EPO) and the myeloid growth factors G- and 
GM-CSF. In responding patients, the use of EPO is able to 
increase quality of life in patients with chronic symptomatic 
anaemia of cancer by treatment or prevention of chemo­
therapy-induced anaemia. Furthermore, application of EPO 
is able to facilitate autologous blood donation in patients 
scheduled for elective surgery if their requirement of blood 
transfusions is highly probable, and in particular for Jehovah’s 
witnesses and other persons who reject donations of allo­
geneic blood.
Currently, the major indications of G-CSF and GM-CSF 
are in the prophylaxis of neutropenic fever in patients who are 
treated with regimens which are likely to produce this com­
plication, and in preventing the recurrence of neutropenic 
fever in patients who developed an infection in a previous 
cycle, and in whom dose reduction would be inappropriate. It 
has been shown in randomised studies that these drugs will 
increase the ability to administer chemotherapy without dose 
reductions and delays, which is probably important in the 
curative setting, but not crucial in the palliative setting. The 
phase III studies done in this context were not designed to
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look for differences in survival but to detect differences in the 
frequency and severity of febrile neutropenia. Restriction of 
HGF administration to secondary prevention (e.g. following 
at least one episode of severe marrow aplasia) is usually 
recommended. Primary prophylaxis should only be consid­
ered in some cases* e.g. in patients with poor bone marrow 
tolerance, The routine use of HGFs in the treatment of 
established febrile neutropenia is not indicated. However, 
patients with life-threatening syndromes of neutropenic 
infections, e.g. septicaemia* bacterial pneumonia or with 
fungal infections* might benefit from their application. The 
use of HGFs in afebrile neutropenic patients has been inves­
tigated in at least one placebo-controlled randomised trial in 
several tumour types and lymphomas and, although it shor­
tened the duration of severe chemotherapy-induced neutro­
penia* it did not impact on clinical outcome.
The use of HGF mobilised stem cells for stem cell rescue 
after high-dose chemotherapy has dramatically reduced the 
transplant-related morbidity. This may lead to an increased 
application in the treatment of chemosensitive solid tumours 
as well as haematological neoplasms. Results of randomised 
studies should be awaited before conclusions can be drawn 
on the efficacy of HGF support after PBSC reinfusion.
More research is warranted to improve the pharmacoeco- 
nomic evaluation in clinical practice. These ought to include 
not only cost-minimisation analysis (e.g. selection of the least 
costly intervention among those shown to be of equal benefit) 
or cost-effectiveness (e.g. comparison of interventions where 
benefit can be expressed in one common natural unit like life- 
years saved), but also cost-utility analysis (e.g. quality adjus­
ted life-years) and cost-benefit analysis (comparison of inter­
ventions, where costs and benefits are measured in financial 
terms and net gains/losses can be calculated) [149].
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